89bio Unveils Bullish Long-Term Data for NASH Candidate

[cafead]

via On Monday, 89bio announced positive topline data from the Phase IIb trial of its candidate treatment for nonalcoholic steatohepatitis. The biotech said that at week 48 in the trial, known as ENLIVEN, both the 30 mg weekly dosage of pegozafermin and the 44 mg dose given every two weeks had “demonstrated statistically significant improvements across key markers of liver health.” Pegozafermin is a glycoPEGylated analog of fibroblast growth factor 21 (FGF21).

article source